Apixaban
Pulmonary Embolism
Medical University of GdanskSmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Pulmonary Embolism cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tranexamic Acid Albert Einstein College of Medicine | Phase 4 | BB |
FONDAPARINUX Johns Hopkins University | Phase 2 | BB |
HEPARIN Johns Hopkins University | Phase 4 | B |
Enoxaparin Medical University of Gdansk | Phase 1/2 | B |
XENON Thunder Bay Regional Health Research Institute | Early Phase 1 | C |
View all 14 →
Same molecule, other indications
Apixaban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →